Nine additional biopharma companies signed most-favored-nation (MFN) pricing agreements with the Trump administration, bringing expansion of the policy beyond the largest drugmakers. The new signatories include Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB. The agreements commit participants to sell new medications in the U.S. at prices comparable to the lowest in peer countries and to offer Medicaid drugs at most-favored-nation pricing. The White House framed the deals as a mechanism to avoid tariffs and participation in CMS pilot programs under review. The MFN rollout’s scope—along with the administration’s claim of broad U.S. market coverage—raises planning pressure for companies balancing pricing strategy, launch timing, and supply commitments.